Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)
Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · May 18, 2006
Trial Information
Current as of June 30, 2025
Unknown status
Keywords
ClinConnect Summary
Background:
Existing criteria for AS/SpA such as mod. New York, ESSG, or Amor criteria for classification and/or diagnosis of spondyloarthritis have limitations when applied to early disease. Moreover, MRI is not part of any of the established criteria and the precise role of MRI in early axial disease has not been fully defined yet. Even less is known about sacroiliac (SI) changes in SpA patients with peripheral symptoms. A pilot study using data from 'paper patients' led to new candidate criteria for early spondyloarthritis. Subsequently, the members of the ASAS International Working Gro...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Include newly referred patients if:
- • Onset of symptoms (back pain/arthritis/enthesitis) \< 45 years
- * Undiagnosed disease with the following symptoms:
- • chronic back pain (duration of back pain more than 3 months)
- • and/or peripheral arthritis (asymmetric arthritis/predominantly of the lower limbs)
- • and/or enthesitis
- • and/or dactylitis
- Exclusion Criteria:
- • No symptoms such as specified in inclusion criteria: back pain, arthritis, enthesitis
- • Definite diagnosis
About Charite University, Berlin, Germany
Charité - Universitätsmedizin Berlin is a leading academic medical center in Germany, renowned for its commitment to excellence in research, education, and patient care. As one of Europe's largest university hospitals, Charité integrates cutting-edge clinical practices with innovative research initiatives, fostering interdisciplinary collaboration across various medical fields. The institution is dedicated to advancing healthcare through rigorous clinical trials, contributing to the development of new therapies and treatment protocols. With a strong emphasis on translational medicine, Charité aims to bridge the gap between scientific discovery and practical application, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dublin, , Ireland
Maastricht, , Netherlands
Amsterdam, , Netherlands
Herne, , Germany
Cleveland, Ohio, United States
Gent, , Belgium
Sao Paulo, , Brazil
Edmonton, Alberta, Canada
Toronto, Ontario, Canada
Beijing, , China
Guangzhou, , China
Bogota, , Colombia
Hvidovre, , Denmark
Marseille, , France
Paris, , France
Berlin, , Germany
Berlin, , Germany
Budapest, , Hungary
Semarang, , Indonesia
Firenze, , Italy
Reggio Emilia, , Italy
Scafati (Sa), , Italy
Mexico City, , Mexico
Hg Ijmuiden, , Netherlands
Córdoba, , Spain
Madrid, , Spain
Zürich, , Switzerland
Beitou Dist. Taipei, , Taiwan
Taichung City, , Taiwan
Bornova, , Turkey
Elazig, , Turkey
Izmir, , Turkey
Glasgow, , United Kingdom
Goodmayes, , United Kingdom
Leeds, , United Kingdom
Patients applied
Trial Officials
Martin Rudwaleit, MD
Principal Investigator
Universitatsmedizin Berlin, Charité Campus Benjamin-Franklin, Med. Clinic I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
Joachim Sieper, MD
Principal Investigator
Charité Universtaetsmedizin Berlin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials